The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk - A European multicentre study on treatment-resistant major depressive disorder

European Archives of Psychiatry and Clinical Neuroscience

Volumn 263, Issue 5, 2013, Pages 385-391

  Höfer, Peter ^a   Schosser, Alexandra ^a   Calati, Raffaella ^b   Serretti, Alessandro ^b   Massat, Isabelle ^c   Kocabas, Neslihan Aygun ^c,d   Konstantinidis, Anastasios ^a   Linotte, Sylvie ^e   Mendlewicz, Julien ^e   Souery, Daniel ^e   Zohar, Joseph ^f   Juven Wetzler, Alzbeta ^f   Montgomery, Stuart ^g   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d GAZI UNIVERSITY   (Turkey)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f SHEBA MEDICAL CENTER   (Israel)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CYP1A2; CYP2C19; CYP2C9; CYP2D6; Cytochrome genes; Pharmocogenetics; Suicidality

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GENOMIC DNA;

ADULT; AGED; ARTICLE; CAUCASIAN; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; REMISSION; RISK; SUICIDE; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

EID: 84881310365     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-012-0375-y     Document Type: Article

References (45)

1. WHO (2012) Programmes and projects, mental health. http://www.who.int/ mental-health/management/depression/definition/en/ Accessed 17th March 2012
2. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):655-679 (Review)
3. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J (1999) Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9(1-2):83-91 (Review) (Pubitemid 29073687)
4. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J, Group for the Study of Resistant Depression (2007) Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68(7):1062-1070 (Pubitemid 47340327)
5. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163(1):28-40
6. Eurostat: Causes of death in the EU(2006) EUROSTAT. Statistics in focus - Population and social conditions. 10:1-11. http://epp.eurostat.ec.europa.eu/ cache/ITY-OFFPUB/KS-NK-06-010/EN/KS-NK-06-010-EN.PDF. Accessed 12th January 2012
7. Hawton K, van Heeringen K (2009) Suicide. Lancet 373(9672):1372-1381
8. Harris EC, Barraclough B (1997) Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 170:205-228 (Pubitemid 27117683)
9. Suominen K, Isometsä E, Suokas J, Haukka J, Achte K, Lönnqvist J (2004) Completed suicide after a suicide attempt: a 37-year follow-up study. Am J Psychiatry 161(3):562-563 (Pubitemid 38326113)
10. Kapusta ND, Tran US, Rockett IR, De Leo D, Naylor CP, Niederkrotenthaler T, Voracek M, Etzersdorfer E, Sonneck G (2011) Declining autopsy rates and suicide misclassification: a cross-national analysis of 35 countries. Arch Gen Psychiatry 68(10):1050-1057
11. Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25(4):193-200 (Pubitemid 38519910)
12. Ingelman-Sundberg M, Sim SC (2010) Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun 396(1):90 (Review)
13. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9(5):442-473 (Review) (Pubitemid 38903502)
14. Holsboer F (2008) How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9(8):638-646
15. Schosser A, Kasper S (2009) The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 24(6):277-288 (Review)
16. Porcelli S, Fabbri C, Spina E, Serretti A, De Ronchi D (2011) Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 7(9):1101-1115 (Review)
17. Zobel A, Maier W (2010) Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci 260(5):407-417
18. Illi A, Poutanen O, Setälä-Soikkeli E, Kampman O, Viikki M, Huhtala H, Mononen N, Haraldsson S, Koivisto PA, Leinonen E, Lehtimäki T (2011) Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? Eur Arch Psychiatry Clin Neurosci 261(2):95-102
19. Chiesa A, Crisafulli C, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Jun TY, Serretti A, Pae CU (2012) Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur Arch Psychiatry Clin Neurosci 262(4):305-311
20. Licinio J, Wong ML (2011) Pharmacogenomics of antidepressant treatment effects. Dialogues Clin Neurosci 13(1):63-71
21. Mendlewicz J, Crisafulli C, Calati R, Kocabas NA, Massat I, Linotte S, Kasper S, Fink M, Sidoti A, Scantamburlo G, Ansseau M, Antonijevic I, Forray C, Snyder L, Bollen J, Montgomery S, Zohar J, Souery D, Serretti A (2012) Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. Neurosci Lett 516(1):85-88
22. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP (2008) Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 3(4):e1872 (Pubitemid 351943829)
23. Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D (2009) Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 24(5):250-256
24. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL (2010) Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11(4):537-546
25. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496-526 (Pubitemid 350116943)
26. Binder EB, Holsboer F (2006) Pharmacogenomics and antidepressant drugs. Ann Med 38:82-94
27. Spina E, Santoro V, D'Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206-1227
28. Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Kasper S (2012) European group for the study of resistant depression (GSRD) - Where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 22(7):453-468
29. Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, Papageorgiou K, Linotte S, Mendlewicz J, Souery D, Zohar J, Juven-Wetzler A, Montgomery S, Kasper S (2012) The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder - a European multicenter study. Eur Neuropsychopharmacol 22(4):259-266
30. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
31. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behaviour genetics research. Behav Brain Res 125:279-284 (Pubitemid 33000466)
32. McGuffin P, Marusic A, Farmer A (2001) What can psychiatric genetics offer suicidology? Crisis 22(2):61-65
33. Bondy B, Buettner A, Zill P (2006) Genetics of suicide. Mol Psychiatry 11(4):336-351
34. Brent DA, Mann JJ (2006) Family genetic studies, suicide, and suicidal behaviour. Am J Med Genet C Semin Med Genet 133C(1):13-24
35. Butler AW, Breen G, Tozzi F, Craddock N, Gill M, Korszun A, Maier W, Middleton LT, Mors O, Owen MJ, Perry J, Preisig M, Rice JP, Rietschel M, Jones L, Farmer AE, Lewis CM, McGuffin P (2010) A genome wide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. Am J Med Genet B Neuropsychiatr Genet 153B(8):1465-1473
36. Davies S, Naik PC, Lee AS (2001) Depression, suicide, and the national service framework. BMJ 322(7301):1500-1501 (Pubitemid 32588342)
37. Fu Q, Heath AC, Bucholz KK, Nelson EC, Glowinski AL, Goldberg J, Lyons MJ, Tsuang MT, Jacob T, True MR, Eisen SA (2002) A twin study of genetic and environmental influences on suicidality in men. Psychol Med 32(1):11-24 (Pubitemid 33150500)
38. Zackrisson AL, Lindblom B, Ahlner J (2010) High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 88(3):354-359
39. Peñas-Lledó EM, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda F, Llerena A (2011) High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 16(7):691-692
40. Peñas-Lledó EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-García E, Llerena A (2012) CYP2D6 and the severity of suicide attempts. Pharmacogenomics 13(2):179-184
41. Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004) Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59(11):803-807 (Pubitemid 38221657)
42. Currier D, Mann JJ (2008) Stress, genes and the biology of suicidal behavior. Psychiatr Clin N Am 31(2):247-269 (Review) (Pubitemid 351551422)
43. Harriss L, Hawton K, Zahl D (2005) Value of measuring suicidal intent in the assessment of people attending hospital following self-poisoning or self-injury. Br J Psychiatry 186:60-66 (Pubitemid 40070545)
44. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195-235 (Review)
45. Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S, Baune BT, Arolt V, Müller-Myhsok B, Holsboer F, Binder EB (2012) Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology 37(3):797-807